Inovio Pharmaceuticals Inc Share Price Nyse
Equities
INO
US45773H2013
Biotechnology & Medical Research
Sales 2024 * | 604K 50.42M | Sales 2025 * | 8.03M 670M | Capitalization | 294M 24.56B |
---|---|---|---|---|---|
Net income 2024 * | -99M -8.26B | Net income 2025 * | -93M -7.76B | EV / Sales 2024 * | 487 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 36.6 x |
P/E ratio 2024 * |
-2.95
x | P/E ratio 2025 * |
-3.76
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
Latest transcript on Inovio Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 25/19/25 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 01/02/01 |
Chief Tech/Sci/R&D Officer | - | 01/07/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 01/03/01 |
Lota Zoth
BRD | Director/Board Member | 64 | 01/18/01 |
Jay Shepard
BRD | Director/Board Member | 65 | 15/20/15 |
1st Jan change | Capi. | |
---|---|---|
+29.93% | 48.16B | |
-0.66% | 41.73B | |
+43.62% | 41.03B | |
-5.31% | 28.77B | |
+10.04% | 25.59B | |
-22.49% | 18.96B | |
+9.31% | 12.92B | |
+28.69% | 12.03B | |
-2.31% | 11.77B |